Early use of statins in acute coronary syndromes

被引：18

作者：

Joshua M. Spin

Randall H. Vagelos

机构：

[1] Stanford University Medical Center, Flak CVRB-279, Stanford

来源：

Current Atherosclerosis Reports | 2003年 / 5卷 / 1期

关键词：

Statin; Acute Coronary Syndrome; Simvastatin; Pravastatin; Statin Therapy;

D O I：

10.1007/s11883-003-0068-0

中图分类号：

学科分类号：

摘要：

This review examines the use of statin medications early in the clinical course of acute coronary syndrome (ACS). Available data demonstrate that there are clear clinical benefits to this practice. Numerous previous studies have documented the primary and secondary benefits of statins in the prevention of coronary events. Recent trials show that when statins are used during hospital admissions for ACS, patients experience decreased recurrent myocardial infarction, lower death rates, and fewer repeat hospitalizations for ischemia or revascularization. Several studies suggest that the positive effects of statins on plaque stabilization, inflammation, thrombosis, and endothelial function may be independent of lipid levels. There is also an emerging view that beneficial lipid-lowering with statins in high-risk patients has no lower limit. This information suggests that all patients admitted for ACS should be treated with statins, regardless of cholesterol levels. Copyright © 2003 by Current Science Inc.

引用

页码：44 / 51

页数：7

共 60 条

[31]

Newby D.E., Witherow F.N., Wright P.A., Et al., Hypercholesterolemia and lipid lowering treatment do not affect the acute endogenous fibrinolytic capacity in vivo, Heart, 87, pp. 48-53, (2002)

[32]

Undas A., Brummel K.E., Musial J., Et al., Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor VIII, and by enhancing factor Va inactivation, Circulation, 103, pp. 2248-2253, (2001)

[33]

Szczeklik A., Musial J., Undas A., Et al., Inhibition of thrombin generation by simvastatin and lack of additive effects of aspirin in patients with marked hypercholesterolemia, J. Am. Coll. Cardiol., 33, pp. 1286-1293, (1999)

[34]

Notarbartolo A., Davi G., Averna M., Et al., Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia, Arterioscleros. Thromb. Vasc. Biol., 15, pp. 247-251, (1995)

[35]

Colli S., Eligini S., Lalli M., Et al., Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis, Arterioscleros. Thromb. Vasc. Biol., 17, pp. 265-272, (1997)

[36]

Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS), Circulation, 97, pp. 1440-1445, (1998)

[37]

Sheperd J., Cobbe S.M., Ford I., Et al., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia, New Engl. J. Med., 333, pp. 1301-1307, (1995)

[38]

Downs J.R., Clearfield M., Weis S., Et al., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels, JAMA, 279, pp. 1615-1622, (1998)

[39]

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S), Lancet, 344, pp. 1383-1389, (1994)

[40]

Sacks F.M., Pfeffer M.A., Moye L.A., Et al., The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels, N. Engl. J. Med., 335, pp. 1001-1009, (1996)

← 1 2 3 4 5 6 →